Osteoporosis International

, Volume 22, Issue 2, pp 373–390

Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report

  • R. Rizzoli
  • K. Åkesson
  • M. Bouxsein
  • J. A. Kanis
  • N. Napoli
  • S. Papapoulos
  • J.-Y. Reginster
  • C. Cooper
Open Access
Position Paper

Abstract

Summary

This paper reviews the evidence for an association between atypical subtrochanteric fractures and long-term bisphosphonate use. Clinical case reports/reviews and case–control studies report this association, but retrospective phase III trial analyses show no increased risk. Bisphosphonate use may be associated with atypical subtrochanteric fractures, but the case is yet unproven.

Introduction

A Working Group of the European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis and the International Osteoporosis Foundation has reviewed the evidence for a causal association between subtrochanteric fractures and long-term treatment with bisphosphonates, with the aim of identifying areas for further research and providing recommendations for physicians.

Methods

A PubMed search of literature from 1994 to May 2010 was performed using key search terms, and articles pertinent to subtrochanteric fractures following bisphosphonate use were analysed.

Results

Several clinical case reports and case reviews report a possible association between atypical fractures at the subtrochanteric region of the femur in bisphosphonate-treated patients. Common features of these ‘atypical’ fractures include prodromal pain, occurrence with minimal/no trauma, a thickened diaphyseal cortex and transverse fracture pattern. Some small case–control studies report the same association, but a large register-based study and retrospective analyses of phase III trials of bisphosphonates do not show an increased risk of subtrochanteric fractures with bisphosphonate use. The number of atypical subtrochanteric fractures in association with bisphosphonates is an estimated one per 1,000 per year. It is recommended that physicians remain vigilant in assessing their patients treated with bisphosphonates for the treatment or prevention of osteoporosis and advise patients of the potential risks.

Conclusions

Bisphosphonate use may be associated with atypical subtrochanteric fractures, but the case is unproven and requires further research. Were the case to be proven, the risk–benefit ratio still remains favourable for use of bisphosphonates to prevent fractures.

Keywords

Atypical Bisphosphonate Femur Low trauma Osteoporosis Subtrochanteric 

Introduction

Treatment with bisphosphonates significantly reduces the risk of fractures in men and women with osteoporosis. The evidence is based on high-quality phase III randomized controlled trials (RCTs) with fracture as an endpoint [1, 2, 3, 4, 5, 6, 7, 8, 9, 10]. The benefits of bisphosphonates also extend to other disorders of bone metabolism such as glucocorticoid-induced osteoporosis [11], Paget’s disease [12] and bone metastases [13, 14].

Treatment with bisphosphonates is not without adverse effects, but they are generally minor and occur in a minority of patients. The most common adverse effect is gastrointestinal upset with the oral formulations, the frequency of which decreases with intermittent treatment such as once-weekly or monthly regimens. Intravenous (IV) administration of nitrogen-containing bisphosphonates may induce an acute phase reaction which manifests as fever, myalgia and arthralgia, although these side effects usually resolve within a few days of onset [3, 7, 15]. High doses of bisphosphonates given intravenously may impair renal function, and the kidney is a major route of elimination of the bisphosphonates. For this reason, bisphosphonates are not recommended for use in patients with severe renal impairment [16, 17, 18]. The use of bisphosphonates has been associated with osteonecrosis of the jaw, but most cases have occurred in patients receiving high-dose IV bisphosphonates for neoplastic bone disease, and osteonecrosis of the jaw has rarely been reported in patients with benign bone diseases [19, 20]. An increased risk of atrial fibrillation has been reported for zoledronic acid [3], but the association may be coincidental [7]. Other uncommon or rare side effects of bisphosphonates include anaemia [21], urticaria [22, 23] and symptomatic hypocalcaemia [22].

In recent years, several clinical case reports and case reviews have reported an association between atypical fractures in patients receiving treatment with bisphosphonates. The majority of these cases have described fractures at the subtrochanteric region of the femur [24, 25, 26, 27, 28, 29, 30, 31].

Against this background, the aim of this report was to critically review the evidence for an increased incidence of subtrochanteric fractures after long-term treatment with bisphosphonates, to identify gaps in our knowledge that warrant further research and to provide guidance for healthcare professionals. A PubMed search of literature from 1994 to May 2010 was performed using the search terms ‘bisphosphonate(s)’ AND/OR ‘alendronate’ AND/OR ‘risedronate’ AND/OR ‘ibandronate/ibandronic acid’ AND/OR ‘zoledronate/zoledronic acid’ AND/OR ‘subtrochanter(ic)’ AND ‘fracture’ AND/OR ‘femur/femoral’ AND/OR ‘atypical’ AND/OR ‘low-trauma’ AND/OR ‘low-energy’. Scientific papers pertinent to subtrochanteric fractures following bisphosphonate use were analysed and included in the evidence base.

Characteristics of subtrochanteric fractures

Subtrochanteric fractures have been defined as occurring in a zone extending from the lesser trochanter to 5 cm distal to the lesser trochanter [32]. However, this anatomical classification of subtrochanteric fracture has several variations [33, 34], resulting in variable definitions in published studies [26, 30, 35].

Regardless of the definition used, many case reports and case reviews have suggested that there are several common features of subtrochanteric fractures associated with bisphosphonate use. Major features were that the fractures arose with minimal or no trauma and, on radiography, the fracture line was transverse. Minor features were that fractures were commonly preceded by prodromal pain and, on radiographs, there appeared beaking of the cortex on one side and bilateral thickened diaphyseal cortices [26, 28, 36, 37, 38, 39]. This fracture pattern has often been referred to as an ‘atypical subtrochanteric fracture’ [40, 41, 42] although, as reviewed below, the distinction between typical and atypical subtrochanteric fractures has not yet been firmly established.

It is worth noting that, on radiography, the appearance of atypical subtrochanteric fractures is similar to that of stress fractures, including a periosteal reaction, linear areas of bone sclerosis and a transverse fracture line. Prodromal pain prior to diagnosis is also common [43]. However, stress fractures are more commonly associated with repeated episodes of increased activity (e.g. participation in sports). Nevertheless, stress fractures due to non-traumatic loading in patients with low bone density do occur (insufficiency fractures) [43]; thus, the terms ‘atypical’ and ‘stress’ are often used interchangeably or in conjunction to describe subtrochanteric fractures in this context. However, this terminology also requires clarification, as not all stress fractures are atypical.

Epidemiology of subtrochanteric fractures

Subtrochanteric fractures are a relatively rare type of hip fracture [44, 45, 46], usually resulting from high-energy trauma, pathologic fracture or, in the elderly, low-energy injury involving osteoporotic bone. Several series report the incidence of this fracture [25, 26, 27, 28, 30, 36, 37, 47], although the definition of the subtrochanteric site has varied. Nieves et al. reported a large, 11-year epidemiological study of fractures of the hip, subtrochanter, femoral shaft and distal femur in the US population aged ≥50 years using National Hospital Discharge Survey data from the National Center for Health Statistics and MarketScan® (medical claims experience) data [46]. Of all femoral fractures, 3% were at the subtrochanteric region, 5% at the femoral shaft, 5% at the distal femur and 87% were at the proximal femur (i.e. hip). Importantly, this study classified fractures solely according to their location in the femur and did not evaluate the fracture patterns radiographically. Thus, they were not able to determine the incidence of ‘typical’ vs ‘atypical’ subtrochanteric fractures. In men and in women, the incidence rate of each type of fracture remained stable over 5 years but increased exponentially with age (Fig. 1). Each fracture type was more prevalent in women than in men. Seventy-five percent of all femur fracture cases were in women. The mean age at fracture was 80 years old, and those with a subtrochanteric fracture were of a similar age to those with a hip fracture.
Fig. 1

Age-specific incidence of femoral fractures according to fracture site in men (X) and women (O) aged ≥50 years (adapted from Nieves et al. [46])

Leung et al. published a retrospective analysis that aimed to document the incidence of low-trauma subtrochanteric or femoral diaphyseal fractures in a Hong Kong hospital over a 5-year period [42]. In all, 88 cases of subtrochanteric fractures and 66 of diaphyseal fractures were identified, accounting for 3.9% and 2.9% of all recorded osteoporotic fractures, respectively.

Thus, although the incidence of subtrochanteric fractures is much lower than other femoral fractures, they are not rare and account for about 3% of all femoral fractures in the elderly. If these estimates were applied to the UK, then more than 2,000 subtrochanteric fractures are expected to occur each year [48], and approximately 48,000 are expected annually worldwide [49].

Subtrochanteric fractures and bisphosphonate exposure

Case reports and case reviews

Twenty-six published case reports and case reviews were identified that were considered relevant, a similar number to that identified in a recent review by Giusti et al. [50].

Concern about bisphosphonate use in relation to atypical subtrochanteric fractures arose from case reports that described patients with subtrochanteric fractures who had been exposed to bisphosphonates, particularly long-term treatment with alendronate (Fosamax®/Fosavance®, alendronate sodium, Merck Sharp & Dohme Limited). The association between long-term bisphosphonate use and unusual diaphyseal fractures was first described by Odvina et al. in 2005 [31] who reported nine patients with osteoporosis or osteopenia who had been treated with alendronate for 3–8 years and sustained atraumatic fractures in the course of their normal daily activities. Three patients had fractures of the femoral shaft and two had fractures of the proximal femur. Of these five patients, fracture healing was radiographically assessed in four. All four patients had delayed or absent fracture healing ranging from 4 months to 2 years while on alendronate treatment.

This and subsequent case reports are summarized in Table 1. The mean and median age of patients was 65 years (range 35–85). All cases involved treatment with alendronate, except for five patients who took risedronate (Actonel®, risedronate sodium, Procter and Gamble Pharmaceuticals) and three who took pamidronate (Aredia®, pamidronate disodium, Novartis Pharmaceuticals Limited). One patient had been taking ibandronate (Bonviva®/Boniva®, ibandronic acid, Roche) for 1 year following long-term alendronate use, and one had been taking risedronate for 5 years following 7 years of pamidronate use. There were no published case reports of subtrochanteric fractures following the use of once-yearly zoledronic acid 5 mg (Aclasta®/Reclast®, zoledronic acid anhydrous, Novartis Pharmaceuticals Limited), although cases following treatment with the monthly 4-mg dose have been reported [36, 38]. The mean and median duration of bisphosphonate use was 7.3 and 7.5 years, respectively (range 1–16), and the majority of patients had unilateral fractures (29 out of 43; 67.4%).
Table 1

Case reports of incidents of subtrochanteric fracture following bisphosphonate use (all cases in women unless otherwise indicated)

Reference

Total patients (patients ST/FS/PF fracture)

Age (years)

Location

Radiographic features

Bilateral?

Prodromal symptoms (duration)

Osteoporosis diagnosis?

Prior bisphosphonate

Duration of use (years)

Concomitant therapy

Healing (months of follow-up)

Odvina et al. [31]

9 (5)

52

Femoral shaft

 

No

 

No (osteopenia)

ALN

8

Ca, D

No (9)

68a

Femoral shaft

Yes

Yes

ALN

8

Ca, D

No (8)

67

Femoral shaft

Yes

No (osteopenia)

ALN

5

Oestrogen, Ca, D

Yes (5)

49

Proximal femur

No

Yes (GIO)

ALN

3

Pred, Ca, D

No (8)

64

Proximal femur

No

Yes (GIO)

ALN

4

Pred, Ca, D

Yes (3)

Husada et al. [51]

1

72

Femoral shaft

Cortical thickening in lateral mid-shaft of contralateral femur

Yes

Severe pain in back and hip (1 month)

Yes

ALN

Not specified

Ca, amlodipine, metaprolol, aspirin

 

Schneider [52]

1

59

Upper femur

Cortical thickening

No

Moderate pain in thigh (3 months)

No (family history of osteoporosis)

ALN

7

Ca, hormone replacement therapy

Yes (>9)

Armamento-Villareal et al. [53]

1

35a

Subtrochanteric femur

 

No

  

ALN

6

Ca

No (36)c

Cheung et al. [54]

1

82

Femoral shaft

 

No

 

Yes

ALN

10

Ca, glucosamine, chondroitin

 

Demiralp et al. [55]

1

65

Femoral shaft

Fracture line, callus, cortical thickening, bowing deformity

Yes

Incapacitating bilateral femoral shaft pain (1.5 months)

Yes

ALN

7

Ca, D, steroid, thyroxine replacement therapy

 

Lee et al. [56]

1

73

Femoral diaphysis

 

No

Bilateral groin pain, difficulty walking (10 months)

Yes

ALN

1.5

 

Yes

Sayed-Noor and Sjoden [57]

1

72

Subtrochanteric femur

Cortical thickening of lateral femoral cortex, medial beaking at fracture site

No

Diffuse pain in hips and thighs (18 months)

Yes

ALN

7

Ca

No (3)/yes (6)

Visekruna et al. [39]

3

51

Femoral metadiaphysis

 

Yes

Bilateral, lateral hip pain

 

ALN

5

Pred

No (3 while on ALN; 12 after stopping ALN)

62

Femoral metadiaphysis

Yes

Bilateral thigh pain

ALN

10

Raloxifene, pred

Yes (12)d

75

Femoral metadiaphysis

No

 

ALN

10

Pred

No (22)

Odvina et al. [58]

13 (11)

57

Subtrochanteric, contralateral femur shaft (3 years later)

Cortical thickening

Yes

Pain at fracture site (1–6 months)

No (osteopenia)

ALN

6

Ca, D

Yes (36)

74

Femoral shaft

Cortical thickening

No

 

Yes

ALN

10

Ca, D

No

67

Femoral shaft

Cortical thickening

No

Pain at fracture site (1–6 months)

Yes

RIS

>5

Ca, D

Yes (6)

58

Femoral shaft (fractured twice in 3 years)

Cortical thickening

No

Pain at fracture site (1–6 months)

No

ALN

7

Ca, D, tamoxifen

Yes (6)

62

Femoral shaft

Cortical thickening

No

 

No (osteopenia)

RIS

2

Ca, D, tamoxifen

 

63

Femoral shaft

Cortical thickening

No

 

Yes

ALN

10

Ca, D, oestrogen

Yes (6)

72

Femoral shaft

Cortical thickening

No

Pain at fracture site (1–6 months)

Yes

ALN

9

Ca, D, oestrogen

Yes

76

Femoral shaft

Cortical thickening

No

 

Yes (GIO)

ALN

11

Ca, D, pred

Yes (12)

72

Left and right femoral shaft

Cortical thickening

Yes

Pain at fracture site (1–6 months)

Yes (GIO)

ALN

10

Ca, D, pred

Yes

77

Femoral shaft

Cortical thickening

No

 

Yes (GIO)

ALN

9

Ca, D, pred

Yes

38

Left and right femoral shaft

Cortical thickening

Yes

 

Yes (GIO)

ALN

3

Ca, D, pred

Yes

Ali and Jay [59]

1

82

Femoral shaft

Cortical thickening

No

  

ALN

8

 

Yes (3)

Goddard et al. [60]

1

67

Femoral diaphysis

Cortical thickening, unicortical beaking

No

  

ALN

16

 

Yes (12)

Ibandronate

1

Sayed-Noor and Sjoden [61]

2

78

Tip of femoral stem

Cortical thickening

No

 

Yes

ALN

9

 

No (6)

55

Subtrochanteric femur

Cortical thickening, medial beaking, cortical thickening on contralateral femur

No

Diffuse pain in thighs, walking difficulties (several months)

Yes

ALN

9

D

Yes (9)

Cermak et al. [62]

4

64

Subtrochanteric femur

Cortical thickening

No

Pain in left thigh (3 months)

No

ALN

5.5

 

Yes (6)

70

Femur

Medial cortical beaking

Yes

Pain in thighs

Yes

ALN

6

 

Yes (4)

Other femur (3 months later)

Yes (7)

77

Femoral shaft

Cortical thickening

No

Pain in right thigh

Yes

ALN

12

 

Yes (12)

59

Subtrochanteric femur

Cortical thickening, medial cortical beaking

No

None

Yes

ALN

10

 

Yes (5)

Bush and Chew [63]

1

85

Subtrochanteric femur

Focal beak of cortical thickening of lateral cortex

No

Limp, persistent pain in anterior thigh (2–3 months)

Yes (GIO)

RIS

>6

Ca, D, pred

Yes (2)

Lee [64]

1

82

Left femoral diaphysis

Horizontal fracture lines at thickest part of femoral cortex extending lateral–medial, followed by short oblique fracture (identical at both sites)

Yes

 

Yes

ALN

8

Ca, D

Yes (5)

Right femoral diaphysis (4 years later)

Edwards et al. [65]

1

60

Right femoral diaphysis

(Taken after initial, right fracture) Minor lateral cortical thickening on left femur

Yes

Mild pain in right thigh before right fracture, none before left fracture

Yes (GIO)

ALN

8

Pred

 

Left femoral diaphysis (2 years later)

Giusti et al. [50]

8

60

Right subtrochanteric femur

 

Yes

Pain in right hip

No

ALN

4

Ca, D, pred, inhaled GCs, esomeprazole, repaglinide, metformine, azathioprine, rosuvastatin

No (6)

Left subtrochanteric femur (9 months later)

36

Femoral shaft

 

No

 

Yes

ALN

8

D, pred, simvastatine, cyclosporine, amlopidine, atenolol, lisinopril

Yes

64

Left and right subtrochanteric femur (1 complete, 1 insufficiency fracture)

 

Yes

Pain in right thigh

No

ALN

2.5

Ca, D, pred, omeprazole, azathioprine, losartan, triamteren, HCT

No (18)

62

Right and left femoral shaftb

 

Yes

Pain in right thigh and hip

Yes

Oral pamidronate

4

Ca, D,

Yes

58

Femoral shaft

 

No

Pain in left thigh

Yes

Intravenous pamidronate

3

Ca, D

No (12)

58

Subtrochanteric femur

 

No

Pain in left hip

No

RIS

5.5

Ca, D, pred, inhaled GCs, omeprazole, pravastatine, ibuprofen

No (12)

72

Left subtrochanteric femur

 

Yes

Pain in left thigh and hip

Yes (GIO)

Oral pamidronate followed by ALN

7 + 5

Ca, D, inhaled GCs, esomeprazole, simvastatine, captopril, irbesartan, clopidogrel

Yes (12)

Right subtrochanteric femur (insufficiency fracture 1 year later)

75

Femoral shaft (insufficiency fracture)

  

Severe pain in left thigh and hip

Yes

RIS

6

Ca, D, esomeprazole, etoricoxib

 

Femoral shaft (insufficiency fracture 1 year later)

Pain in hip

ALN alendronate, BP bisphosphonate, Ca calcium, D vitamin D, FS femoral shaft, GCs glucocorticoids, GIO glucocorticoid-induced osteoporosis, HCT hydrochlorothiazide, PF proximal femur, RIS risedronate, ST subtrochanteric, Pred prednisone

aMale patient

bFirst fracture prior to BP treatment; contralateral fracture following 4 years’ BP treatment; refracture of contralateral femoral shaft 4 years after second fracture

cPatient was prescribed alendronate in 1996 and took it for 6 years. Fracture occurred 1 year after discontinuation and had not completely healed when reported in 2006

dPatient began teriparatide immediately after fracture

In addition to case reports, several case reviews have been published, which are summarized in Table 2. For example, the characteristics of low-trauma subtrochanteric and diaphyseal fractures were studied retrospectively by Neviaser et al. in all patients admitted to a US trauma centre over a 5-year interval (Table 2) [30]. Radiographs were examined by independent experts to identify fractures with a simple, transverse or short oblique pattern in areas of cortical hypertrophy with a cortical beak. The observers were blinded to patient characteristics, including alendronate use. Seventy patients were identified, of whom 25 were treated with alendronate. Nineteen out of 25 (76%) alendronate-treated patients had the radiographic pattern compared with one out of 45 (2%) non-alendronate-treated patients. Thus, the risk of having an ‘atypical’ subtrochanteric fracture pattern was significantly associated with alendronate use (odds ratio = 139; 95% confidence interval (CI) 19–939; p < 0.0001). The mean duration of treatment with alendronate was 6.2 years (6.9 years in those who had the fracture pattern vs 2.5 years in those who did not) [30]. The authors concluded that there are unique features to bisphosphonate-associated fractures.
Table 2

Case reviews of incidents of subtrochanteric fracture following bisphosphonate use (all cases in women unless otherwise indicated)

Reference

Review location/period

Inclusion criteria

Patients eligible (n)

Mean age (years [range])

Fracture location

Radiographic features (n)

Bilateral? (n)

Prodromal symptoms (duration)

OP diagnosis? (n)

Prior BP (duration of use, years)

Concomitant therapy (n)

Goh et al. [26]

2 Singapore hospitals/May 2005–February 2006

ST fracturea due to low-energy trauma

13

        

ALN (9)

66.9 (55–82)

NA

Cortical thickening (6 = lateral, 3 = contralateral)

NR

5 pts (2–6 months)

Yes (3)

ALN (4.2 [2.5–5])

Ca (all); long-term oral steroids (1)

No (4)

Unknown (2)

No ALN (4)

80.3 (64–92)

NA

NR

None

Yes (all)

NA

Ca (2)

Kwek et al. [28]

Singapore hospital/May 2005–January 2007

ST fractureb due to low-energy trauma in patients taking ALN

17

66 (53–82)

NA

Lateral cortical thickening, medial cortical beaking (all)

ST stress fracture (2)

Yes, 13 pts (1 week–24 years)

Yes (10)

ALN (4.4 [2–8]) [1 patient taking RIS after 4 years on ALN]

Ca (all); long-term prednisolone (1)

Femoral shaft stress fracture (1)

No (6)

Femoral shaft fracture (1)

Unknown (1)

Neviaser et al. [30]

US trauma centre/January 2002–March 2007

Low-energy ST and mid-shaft femur fracturesc

70 (11 male)

74.7

ST femur (50)

Lateral cortical thickening, unicortical beaking (20)d

NR

NR

Yes (31)e

ALN (6.2 [1–10]) [25 pts]f

NR

Femoral shaft (20)

Glennon [47]

Australian tertiary hospital, 12 months

ST stress fracture with characteristic radiological/clinical features

6

60–87

NA

Transverse fracture, unicortical beaking, cortical thickening (all)

1 patient

Pain in 5 pts (1 week to 6 months)

NR

ALN (1.5–16) [5 pts]

NR

RIS (>3) [1 pt]

Ing-Lorenzini et al. [27]

Swiss university hospital/2 years

Low-energy ST fracture, history of BP use

8 (7 females)

67.5

ST femur (7)

Cortical thickening, also in contralateral femur in 4 patients

Yes, in 4 patients 0.5–5 years after first fracture

Pain in 2 pts, 1 lateral side, 1 both sides

Yes (all; 1 pt GIO)

ALN alone (1.5–8) [3 pts]

Ca (all), glucocorticoids (4), proton-pump inhibitors (7)

Femoral shaft (1)

ALN (3–10) switched to ibandronate (1 NK)g [3 pts]

RIS (NK) switched to ALN (2) [1 pt]

Pamidronate (5)h [1 pt]

Armamento-Villareal et al. [25]

US medical school/November 2004–March 2007

Low-energy fracture, mainly at cortical sites, 2 years’ BP therapy, bone biopsy

15 (12 females, 3 males)

        

43–75

Femoral shaft (7) [1 male]

 

Yes (2)

NR

NR

ALN (4–10) [6 pts]

Ca (6); vitamin D (6); infliximab (1); triamcinolone (1); tamoxifen (1); levothyroxine (1); fluticasone (1); HCT (1); mometazone (1)

 

Other (9)

    

RIS (2) [1 pt]

 

Capeci and Tejwani [37]

US university hospital/4 years

Bilateral low-energy femoral diaphyseal or ST fracture, long-term ALN

7

61 (53–75)

Simultaneous femoral diaphysis (1)

Cortical thickening, medial beaking (all)

Yes (all)

Thigh pain (4 pts with impending ST stress fractures)

NR

ALN (8.6 [5–13])

None affecting bone metabolism

Sequential ST femur (2)

ST and impending contralateral ST femur (3)

Femoral diaphysis and impending contralateral ST femur (1)

Bunning et al. [36]

US rehabilitation hospital/7 years

Atypical low- or no-impact femoral fracture

4 (1 male)

49–59

Diaphyseal femoral (3); left ST/right diaphyseal femoral (1)

Medial cortical thickening (1)

1 pt

Pain in hip (1–3 months) [all], pain in knee [1 pt]

Yes (all)

None [1 patient]

NR

Pamidronate (0.5)/zoledronic acid 4 mg (>4.5) [1 pt]

ALN (5) [1 pt]

ALN (6) [1 pt]

ALN alendronate, BP bisphosphonate, Ca calcium, GIO glucocorticoid-induced osteoporosis, HCT hydrochlorothiazide, NA not applicable (described in inclusion criteria), NK not known, NR not reported, OP osteoporosis, Pt patient, RIS risedronate, ST subtrochanteric

aIn the region of the femur which extended from the lesser trochanter to the junction of the proximal and middle third of the femoral shaft

bWithin the region of the femur 5 cm distal to the lesser trochanter

cMuller AO classification type 32 and type 31 A3 fractures involving or extending distally to the lesser trochanter

dNineteen had been treated with alendronate

eTwenty-one had been treated with alendronate

fAll females. Eighteen cases confirmed through physician/patient contact. Duration of use established in 16 cases

gOne patient had been on ibandronate for 1 year. One switched to ibandronate 4 months before first fracture in February 2006; one switched 1 year before second fracture in Jan 2008

hStopped 1 year before fracture

Controlled studies

Six studies that utilized control groups were identified that have investigated the association of subtrochanteric fractures with the use of bisphosphonates. In the study of Nieves et al. described above, the rate of subtrochanteric and femoral shaft fractures appeared to be higher than that of other fractures in women taking oral bisphosphonates (Fig. 2) [46], although there is no statistical information provided. It is not known whether excess fractures were due to trauma or not. The study concluded, however, that there was no evidence of an increase in the incidence of subtrochanteric or femoral shaft fracture between 1996 (around the time that bisphosphonates were first introduced) and 2006. Limitations of these data include the lack of radiological and clinical verification and no information on the type of bisphosphonate used or the duration of treatment.
Fig. 2

Medical and prescription drug history in US female fracture patients (2002–2006) during the 1 year before index date (adapted from Nieves et al. [46])

In a study by Leung et al., ten patients with subtrochanteric fractures who had received alendronate were identified over a 5-year period. This included one patient who had taken alendronate for 1 year followed by ibandronate for 2 years [42]. The crude incidence of subtrochanteric/femoral diaphyseal fractures associated with prior bisphosphonate use increased over 5 years from 0% in 2003/2004 to 6% in 2004/2005, 8.6% in 2006/2007 and 25% in 2007/2008. This trend was despite a steady annual incidence of subtrochanteric/femoral diaphyseal fractures. It is difficult to draw meaningful conclusions from these data because of the very small sample size (ten subtrochanteric fractures in patients exposed to a bisphosphonate) and the lack of information on bisphosphonate use at other fracture sites. At best, the study documents the increasing use of bisphosphonates over the time of study.

In a small retrospective case–control study, Lenart et al. aimed to identify an association between low-energy subtrochanteric/femoral shaft fractures (according to the Müller AO classification) and long-term bisphosphonate use [29]. Forty-one low-energy subtrochanteric or femoral shaft fracture cases were identified and matched by age, body mass index and race to one low-energy intertrochanteric and femoral neck fracture each.

Fifteen out of the 41 (37%) cases of subtrochanteric or femoral shaft fracture cases were taking bisphosphonates, compared with nine out of 82 (11%) controls (OR = 4.4; 95% CI 1.8–11.4; p = 0.002). Alendronate was the bisphosphonate taken in all cases. Eight out of nine cases in the control group were taking alendronate (one had previously taken etidronate). A radiographic pattern of a simple transverse or oblique fracture, beaking of the cortex on one side and cortical thickening at the fracture site, was observed in ten of the 15 (67%) subtrochanteric/femoral shaft fracture cases taking bisphosphonate and three of the 26 (11%) subtrochanteric/femoral shaft fracture cases not taking bisphosphonate (OR = 15.3; 95% CI = 3.1–76.9; p < 0.001). The duration of bisphosphonate exposure was significantly longer in patients with this X-ray pattern [29].

Koh et al. carried out a retrospective clinical and radiological review of geriatric hip fracture patients at a Singapore tertiary centre over 4 years to assess features that predispose to complete stress fractures [38]. Thirty-two patients with spontaneous or low-energy fractures with metaphyseal–diaphyseal involvement and on bisphosphonate therapy were identified. All were on alendronate therapy except for one who was on monthly zoledronic acid 4 mg and one who had been on risedronate for 6 years following 4 years of alendronate. Of these, 16 patients (median duration of therapy 4.5 years) had radiographic evidence of lateral cortical thickening. Four had cortical stress lesions on the prefracture radiograph (group F) and 12 had cortical stress lesions on the contralateral femur (group C). The type of bisphosphonate taken by patients according to group was not detailed. All patients in group F experienced prodromal thigh discomfort, compared with 25% of patients in group C (p = 0.019), and radiographic evidence of a stress line across the cortical thickening occurred in 100% and 8% of patients, respectively (p = 0.003). At a median follow-up of 23 months, none of the patients in group C had developed a complete fracture. All of these patients except for one had discontinued bisphosphonate therapy; five had not taken any alternative therapy since discontinuation. Nevertheless, eight out of the 11 were asymptomatic, and no new cortical thickening was detected in any of the patients. The authors concluded that, in people taking long-term bisphosphonate therapy, symptomatic cortical stress reactions accompanied by evidence of a stress line across the cortical thickening suggest an increased risk of a complete stress fracture [38].

In the only population-based study that included radiological review of all cases, Schilcher and Aspenberg studied the incidence of stress fractures at the femoral shaft in bisphosphonate-treated patients in four hospitals in Sweden. Women aged over 55 years with fractures of the femoral diaphysis or subtrochanteric region were identified from the operation registry. Preoperative radiographs were examined to identify stress fractures, defined as a transverse fracture of the femoral shaft with cortical thickening. Of 91,956 women identified, 3,087 bisphosphonate users were identified, of whom five had femoral stress fractures. All of these five patients were aged >75 years, and their mean duration of treatment was 5.8 years [66]. Three patients that were not treated with bisphosphonates had stress fractures. All were aged <75 years. The annual incidence of femoral shaft stress fractures in bisphosphonate users was 1/1,000 per year (95% CI 0.3–2) vs 0.02/1,000 (0.004–0.1) per year in control patients. Thus, the risk of such fractures was estimated to be 46 times greater with bisphosphonate use (95% CI 11–200) [65]. An obvious weakness of the study is that, although the confidence intervals were corrected for sample size, the findings were based on just eight femoral shaft stress fractures. The results thus raise a hypothesis to be tested on larger samples.

A larger study is provided by Abrahamsen et al. who studied the epidemiology of subtrochanteric and diaphyseal femur fractures in patients in Denmark treated with alendronate [67]. However, in contrast to the Schilcher and Aspenberg report, in this study, radiographic fracture patterns were not reviewed, and thus, fractures were identified purely based on their location. In patients aged ≥60 years that had subtrochanteric, diaphyseal femur and hip fractures in 2005, the incidence of subtrochanteric (n = 898) and diaphyseal fractures (n = 720) were similar, and the ratio of high-to-low-energy trauma fractures was the same for each of these fracture types (approximately 2.5:1 for each). Exposure to alendronate was also similar between fracture types (approximately 7% each). Patients with subtrochanteric fractures and diaphyseal fractures were more likely to have taken glucocorticoids in the year before fracture than patients with hip fracture (10.9%, 8.4% and 6.5% of patients, respectively).

In a register-based matched cohort analysis, Abrahamsen et al. investigated whether the increase in risk of ‘atypical’ femur fracture in alendronate-treated patients was greater than the increase in risk of ‘typical’ osteoporotic femur fractures (‘typical’ and ‘atypical’ were not defined). In total, 15,187 patients who took alendronate for ≥6 months after the fracture event (the treatment cohort) were compared with two randomly assigned sex-, age- and fracture-matched controls (n = 10,374). The use of alendronate was associated with an increase in the hazard ratio (HR; adjusted for baseline comorbidities) for both subtrochanteric/diaphyseal fractures (HR = 1.46; 95% CI 0.91–2.35; p = 0.12) and hip fracture (HR = 1.45; 95% CI 1.21–1.74; p < 0.001). Subtrochanteric/diaphyseal fractures were equally common in the alendronate-treated (14% of hip fractures) and control patients (13%; p = 0.70). Both hip fractures and subtrochanteric/diaphyseal fractures were significantly lower in patients with higher adherence (HR = 0.47 [0.34–0.65; p < 0.001] and 0.28 [0.12–0.63; p < 0.01], respectively). In a sub-analysis of 178 compliant (medication possession ratio >80%) patients who took alendronate for >6 years, long-term alendronate use was associated with no change in both hip (HR = 1.24 [0.66–2.34]; p = 0.52) and subtrochanteric/diaphyseal fractures (HR = 1.37 [0.22–8.62]; p = 0.74). The incidence of subtrochanteric/diaphyseal fractures was similar in the long-term alendronate (10%) and control (12.5%) groups (10% vs 12.5%, respectively) [67].

This study, in a large number of patients, does not support the hypothesis that exposure to alendronate is associated with an increased frequency of subtrochanteric fractures compared with controls. However, the same study reported that treatment with alendronate was associated with an increased risk of hip fracture. This should not be interpreted as ‘alendronate causes hip fracture’, but only that high-risk patients are exposed to alendronate. The finding also illustrates the difficulties in the interpretation of retrospective observational studies, particularly accounting for selection bias that likely confounds the other much smaller observational studies.

Randomized controlled trials

Black et al. recently reported an analysis of subtrochanteric and diaphyseal fractures in the Fracture Intervention Trial (FIT) of alendronate and its extension [1, 2, 5, 68] and the HORIZON Pivotal Fracture Trial (PFT) of zoledronic acid 5 mg [3]. Twelve fractures in ten patients were documented in the subtrochanteric or diaphyseal region (Table 3) a combined rate of 2.3 per 10,000 patient-years [69]. However, radiographs were not available to confirm typical vs atypical radiographic features. There was no significant increase over placebo in the risk of subtrochanteric/diaphyseal fractures during the FIT, FIT Long-Term Extension (FLEX) or HORIZON-PFT trials. Compared with placebo, the relative hazard was 1.03 (95% CI 0.1–16.5) for alendronate use in the FIT trial, 1.5 (95% CI 0.3–9.0) for zoledronic acid in the HORIZON-PFT and 1.3 (95% CI 0.1–14.7) for continued alendronate use in the FLEX trial. The interpretation of this analysis is limited by the small number of events and the large confidence intervals.
Table 3

Characteristics of ten patients with 12 low-trauma subtrochanteric or femoral diaphyseal fractures in the FIT, FLEX and HORIZON-PFT trials (adapted from Black et al. [69])

Study

Age (years)

Study medication

Time from randomization to fracture (days [years])

Bilateral?

Prodromal symptoms

Compliance

Concomitant therapy

FIT

75

Placebo

962 (2.6)

  

>75%

None

FIT

69

Alendronate

1,682 (4.6)

  

>75%

None

FLEX

79

Alendronate (first fracture)

1,250 (3.4)

  

Stopped 3 years before first fracture

Alendronate, 6 years (in FIT before FLEX)

Alendronate (second fracture)

1,369 (3.8)

FLEX

80

Alendronate/placebo

1,257 (3.4)

  

Stopped 3 years before fracture

Alendronate, 6 years (in FIT before FLEX)

FLEX

83

Alendronate/alendronate

1,006 (2.8)

  

>75%

Alendronate, 5 years (in FIT before FLEX)

HORIZON

65

Zoledronic acid

454 (1.2)

 

Hip pain

100%

Raloxifene

HORIZON

78

Placebo

1,051 (2.9)

 

Hip pain

100%

None

HORIZON

65

Zoledronic acid

732 (2.0)

  

100%

None

HORIZON

72

Placebo

321 (0.9)

  

100%

Calcitonin

HORIZON

71

Zoledronic acid (2 fractures)

934 (2.6)

Yes

Bone pain

100%

Bisphosphonate and hormone replacement therapy, both before study

Bilezikian et al. reported the incidence of subtrochanteric fractures in the randomized, placebo-controlled phase III studies of risedronate in post-menopausal osteoporosis, which enrolled more than 15,000 patients. In trials of up to 3 years duration, the mean incidence of subtrochanteric fractures was 0.14% in risedronate 2.5-mg treated patients (n = 4,998), 0.13% in risedronate 5-mg treated patients (n = 5,395) and 0.17% in placebo-treated patients (n = 5,363) [70]. In active control studies of risedronate involving various doses (35 mg once weekly, 75 mg on two consecutive days per month, 150 mg once monthly), no subtrochanteric fractures were reported, and the incidence of hip/femoral fractures was similar to that in the placebo-controlled studies [70].

The manufacturers of ibandronate have assessed their clinical trials database to determine the incidence of subtrochanteric and diaphyseal femoral fractures in women taking ibandronate for post-menopausal osteoporosis. Atypical fractures were defined as ‘mostly non-spine fractures including hip or femur fractures in the subtrochanteric region or shaft and occurring without trauma or in association with low-energy trauma’. For femur fractures, subtrochanteric fracture location was considered as atypical for osteoporosis-related fractures, defined as a region below the lesser trochanter and a junction between the proximal and middle third of the femoral shaft. In the pivotal trials (MF 4380, BONE, MOBILE and DIVA) [4, 71, 72, 73], there were nine fracture cases corresponding to these defined locations and characteristics (subtrochanteric, femoral shaft, stress or multiple fractures): six occurred in placebo-treated patients (n = 1,924) and three in ibandronate-treated patients (n = 6,830). In addition, there was one identified case of a femoral shaft fracture in an ibandronate-treated patient in the extension and major phase IIIb trials (MOBILE LTE, DIVA LTE, MOTION and PREVENTION; n = 2,451) [74, 75, 76, 77]. Some fractures were reported without identifying the precise location. However, all of these fractures were associated with trauma and thus did not meet the definition for atypical fractures. An additional 5-year analysis of the marketed regimens of ibandronate (150 mg once monthly and 3 mg IV quarterly) was also carried out from the active comparator-controlled trials and their extensions (MOBILE, DIVA, MOTION, MOBILE LTE and DIVA LTE) [71, 72, 74, 75, 77]. No atypical subtrochanteric/diaphyseal femoral fractures were found for either of the marketed regimens (150 mg, n = 1,279; 3 mg, n = 469).

Pharmacovigilance data

Since fractures are the clinical outcome of osteoporosis and no treatments are fully effective, fractures are expected in treated patients. It is likely, however, that the number of reports through pharmacovigilance will be small. The number of postmarketing reports of atypical stress fractures in association with alendronate to circa July 2008 was 115 (of which 84 were femur fractures) and included a large number of the cases reported in the literature [78].

Bilezikian et al. have reported that in more than 10 years of risedronate post-approval surveillance to September 2008 (18 million patient-years of exposure), the reporting rate for subtrochanteric fractures was <0.1 per 100,000 patient treatment years of exposure [70].

Postmarketing data from the manufacturers of zoledronic acid have revealed a similarly low rate of subtrochanteric fractures with zoledronic acid 5 mg. Using the last cutoff date for worldwide Health Authority Reporting prior to January 2010 (Periodic Safety Update Report v6) and assessing all adverse event reports for zoledronic acid 5 mg (579,501 patient-years of exposure), the rate of femoral subtrochanteric fracture reporting was three per 1,000,000 patient treatment years of exposure.

Postmarketing data from the manufacturers of ibandronate have also revealed a low rate of possible atypical fractures occurring in patients receiving ibandronate for the management of postmenopausal osteoporosis. According to their global safety database as of June 2009, cumulative postmarketing exposure of ibandronate yielded a crude reporting rate of possible atypical fractures of approximately one per 1,000,000 patients. Three of the cases involved alendronate treatment followed by ibandronate treatment and were reported in the case series of Ing-Lorenzini et al. [27].

Regulatory perspective

In July 2008, the Pharmacovigilance Working Party (PhVWP) of the Committee for Medicinal Products for Human Use (CHMP) initiated a class review on bisphosphonates and atypical stress fractures. Marketing Authorization Holders supplied information about all preclinical, clinical and future studies, published case reports, postmarketing data, possible mechanisms and proposed risk-minimization activities. Following a PhVWP review of these data in December 2008, the CHMP concluded that there was an association between atypical stress fractures and long-term use of alendronate, due to the distinct fracture pattern, prodromal pain and poor fracture healing. However, the benefit–risk balance of alendronate use was considered favourable. The CHMP highlighted that there was uncertainty concerning a class effect for other bisphosphonates and that switching of bisphosphonates should be avoided at this time. Ultimately, the CHMP recommended that information about atypical stress fractures should be added to the product information for medicinal products containing alendronate [78]. Consequently, the labelling for alendronate (Fosamax®/Fosavance®, Merck Sharp & Dohme Limited) now includes a special warning/precaution for alendronate use, advising discontinuation of bisphosphonate therapy in patients with stress fracture pending evaluation, based on an individual benefit–risk assessment [22, 79]. Alendronate is the only bisphosphonate for osteoporosis treatment that currently carries this warning.

In addition to the 2008 class review, the EMEA released a statement in August 2009 highlighting their 2010 priorities for drug safety research with regards to the long-term adverse skeletal effects of bisphosphonates: (1) generate methodologies to study the link between bisphosphonate use and long-term adverse skeletal events in human populations and (2) measure the incidence of stress/insufficiency fractures in association with high-dose/long-term use of bisphosphonates by class, compound, mode of administration, dose etc. Methods could include meta-analysis or nested case–control studies [80].

In June 2008, the US Food and Drug Administration (FDA) initiated a review of bisphosphonates for a possible association with increased risk of atypical subtrochanteric femur fractures. All available case reports and clinical trial data were requested from all bisphosphonate drug manufacturers and were reviewed alongside the registry data from the large observational study of Abrahamsen et al. [67]. In March 2010, the FDA announced that the data reviewed had not shown a clear connection between bisphosphonate use and the risk of atypical subtrochanteric fractures. Physicians were urged to continue to follow the labelling when prescribing bisphosphonates and patients were instructed not to discontinue their medication unless instructed to do so by their physician [81].

Pathophysiology of subtrochanteric fractures associated with bisphosphonate use

The pathophysiology of atypical low-trauma subtrochanteric fractures following bisphosphonate use is not known. However, preclinical and clinical studies of the effects of bisphosphonates on bone suggest that there are several possible mechanisms that work either alone or in tandem. The organic matrix of the bone determines its toughness, and this matrix is partly made up of bone collagen, which impacts on the bone’s mechanical properties. Bisphosphonate use may negatively affect collagen by preventing or reducing its maturation [82], although this finding has not been consistently replicated [83]. Bisphosphonates may also affect bone mineralization density distribution (BMDD). The more heterogeneous the BMDD, the slower that cracks in the bone will develop and the lower the risk of new cracks and fractures forming [84]. As bisphosphonate treatment reduces bone turnover, the increase in overall mineralization leads to more homogeneous bone—as evidenced by a narrow BMDD [85, 86]—and thus an increased risk of cracks and fractures. Reduced bone turnover also increases the accumulation of microdamage, as cracks are not repaired [87], and reduces bone toughness, which contributes to the increased susceptibility of bone to new cracks [88, 89, 90]. Finally, bisphosphonates have differing impacts on different types of fracture. Acute fractures of long bone are not affected by bisphosphonates in the initial healing stages [91, 92, 93], as they heal via endochondral ossification. However, stress fractures heal by normal bone remodelling, and thus, bisphosphonates may prevent or delay healing, increasing the likelihood of a complete fracture with little or no trauma. Several reports have reported on bone quality in people with low-trauma fractures taking bisphosphonate therapy.

For example, Odvina et al. reported that cancellous bone histomorphometry in alendronate-treated patients (3–8 years) who sustained spontaneous non-vertebral fractures showed markedly suppressed bone formation, with reduced or absent osteoblastic surface in most patients. Osteoclastic surface was also low in most patients, and eroded surface decreased in half [31]. Odvina et al. reported similar findings in a later report in a comparable patient population [58]. In a case report by Armamento-Villareal et al. of a man who had a low-trauma subtrochanteric fracture after discontinuing 6 years of alendronate treatment, a bone biopsy showed severely decreased trabecular connectivity, a lack of osteoid on trabecular surfaces and an absence of tetracycline labelling [53]. Armamento-Villareal et al. later reported that of 15 bisphosphonate-treated patients (2–10 years; Table 2) who underwent bone biopsies following a low-energy cortical (femoral shaft, pelvis, rib, metatarsal, ankle) fracture, ten had an absence of double-tetracycline label, reduced osteoid surface and thickness suggestive of suppressed trabecular bone remodelling. However, there was no difference in cortical thickness between patients with suppressed (n = 10) and normal (n = 5) turnover [25]. Recent findings by Somford et al., however, suggest an alternative pathophysiology for subtrochanteric fractures associated with bisphosphonate treatment. In a patient who was treated with alendronate for 8 years and subsequently developed spontaneous bilateral subtrochanteric/diaphyseal fractures, biopsies showed a marked decrease in bone formation as expected; however, this was not coupled with the expected decrease in bone resorption. In fact, bone resorption parameters such as osteoclast number were markedly increased in the femur sample. In addition, there was no evidence of hypermineralized bone. This suggests that an imbalance between bone resorption and bone formation at the affected femur—the cause of which is currently unknown—rather than excessive suppression of bone turnover may be the underlying mechanism for subtrochanteric/diaphyseal femoral fractures in bisphosphonate-treated patients [94].

Summary of evidence

The view that bisphosphonates increase the risk of subtrochanteric femoral fractures arises from the case reports and retrospective case reviews that have reported ‘atypical’ subtrochanteric and diaphyseal fractures in patients exposed to bisphosphonates. In all, these data highlight the scope of the problem, i.e. a trend that warrants further investigation. However, the data in their entirety are insufficient proof that long-term bisphosphonate use is the only cause of atypical low-trauma subtrochanteric fractures.

There are several limitations to the existing evidence base: lack of a consensus definition of an atypical subtrochanteric fracture, small numbers of patients involved, lack of radiographs which precludes characterization of the radiographic features of the fractures and incomplete reporting of subject characteristics. In addition, subtrochanteric fractures in general are not atypical fractures; rather, they are part of the natural history of fragility fractures in osteoporosis. They increase in frequency with age in much the same way as does the incidence of other osteoporotic fractures [95]. Although their incidence is much lower than other femoral fractures, they are not rare and account for approximately 3% of all femoral fractures [46]. Thus, the term ‘atypical’ is not synonymous with ‘unexpected’ which is the common interpretation. Rather, the term should be reserved for subtrochanteric fractures that have atypical features, of which some are similar to with those associated with stress.

Therein lies an additional problem in that it has been difficult to provide characteristics of the fracture that are associated with the use of bisphosphonates. Candidate features, which include the prodromal manifestation of incomplete (fissure) fractures, a thickened cortex and a transverse fracture pattern with cortical beaking may be associated with the use of bisphosphonates but, in the absence of blinded evaluation in all cases, may be subject to large observer biases. In addition, in many instances, cases have been complicated, for example, by concomitant exposure to glucocorticoids [25, 26, 27, 28, 31, 39, 50, 55, 58, 63, 65], which appears to be a risk factor for subtrochanteric fractures [46].

In terms of evidence-based medicine, the ultimate arbiter for a causal relationship between subtrochanteric fractures and exposure to bisphosphonates might be expected to derive from information from RCTs. All the information available fail to show an association of this fracture with exposure to bisphosphonates, although all RCTs were completed before attention was drawn to the problem, so the documentation of the sites of fracture and any associated features is inevitably incomplete. Furthermore, the frequency of the event is sufficiently low that even large RCTs are insufficiently powered to identify meaningful associations with drug exposure. Finally, the duration of exposure to bisphosphonates may be too short in the setting of RCTs if, as has been suggested, the complication were to increase in frequency with exposure time. Against this background, data from observational studies might be expected to contribute to our understanding, but such studies are fraught with biases and limitations for which it may be difficult to adjust.

Research agenda

The ultimate question for physicians is what type of patient is at the highest risk of an atypical low-trauma subtrochanteric fracture. Thus far, apart from long-term alendronate therapy, suggested risk factors include glucocorticoid, proton-pump inhibitor or calcitonin use and female gender [26, 46, 67]. Thus, a number of urgent issues and areas for research have been identified as follows:
  1. 1.

    Standardized definition of ‘subtrochanteric fracture’, including a definition of ‘atypical’ and ‘typical’ fractures

     
  2. 2.

    Provision of descriptive epidemiology based on large-scale studies with characterization of radiographic features

     
  3. 3.

    Definition of fracture incidence by femoral location, mechanism of injury and underlying pathology

     
  4. 4.

    Identification of risk factors, with greater clarity as to the precise risk factors in patients taking bisphosphonates

     
  5. 5.

    Pathophysiological studies in relation to risk factors

     
  6. 6.

    Pathophysiological studies at the tissue level, i.e. is the mechanism of atraumatic (insufficiency) fractures different to that of low-trauma fractures?

     
  7. 7.

    Long-term, large, prospective, observational studies to assess incidence of subtrochanteric fractures in bisphosphonate-treated vs bisphosphonate-naïve patients. Methods should include (1) futility analysis and (2) radiographic measurements. Outcomes should include (1) adherence, (2) number needed to harm and (3) assessment of temporal relationship between bisphosphonate treatment and fracture type

     
  8. 8.

    Long-term, large, prospective, observational studies allowing for systematic follow-up of patients with subtrochanteric fractures treated long-term with bisphosphonates, in order to assess fracture healing characteristics (e.g. time to healing, choice of fracture treatment device, adjuvant bone anabolic intervention etc.)

     
  9. 9.

    Large, prospective, randomized, controlled clinical trials of the efficacy and safety of pharmacological treatment (e.g. strontium ranelate, teriparatide) for patients with subtrochanteric fractures

     

Conclusions and recommendations

A sense of proportion may be helpful in alleviating the concerns of the medical community. A plausible scenario is that long-term exposure to bisphosphonates (more than 5 years) increases the risk of subtrochanteric femoral fractures twofold. In the UK, using the guidance of the National Osteoporosis Guideline Group, the relative risk of hip fracture is expected to be approximately threefold increased in postmenopausal women identified for treatment [96]. Assuming that the average population risk of hip fracture is 1% per year in postmenopausal women, then 300 hip fractures are expected for every 10,000 patients identified to be at high risk. If these patients were treated and assuming an effectiveness of bisphosphonates of 36% (RR = 0.64) [97], then 108 hip fractures are averted by treatment (and approximately 750 fractures at other sites). On the debit side, three subtrochanteric fractures (both typical and atypical) are to be expected, which might increase to six if bisphosphonates doubled the risk of all subtrochanteric fractures. Under the assumptions of this scenario, the risk–benefit ratio remains very favourable.

Evidence, including that from an EMEA class review, suggests that alendronate use may potentially increase the risk for atypical, low-trauma subtrochanteric fractures, although it is unclear whether this applies to other bisphosphonates. Irrespective of exposure to bisphosphonates, the occurrence of subtrochanteric fractures is an expected finding in patients with osteoporosis. If atypical fractures do occur, then their characteristics are poorly defined, their causality with bisphosphonate exposure insecure and their frequency rare. Bisphosphonates as the cause of atypical fractures at the subtrochanteric site is therefore still merely a hypothesis, though no less important for that. Clearly more research is required from well-designed prospective observational studies, meta-analyses and nested case–control studies.

Thus, the available evidence does not suggest that the well-known benefits of bisphosphonate treatment are outweighed by the risk of these rare, atypical, low-trauma subtrochanteric fractures. Nevertheless, it is recommended that physicians remain vigilant in assessing their patients treated with bisphosphonates for osteoporosis or associated conditions. They should continue to follow the recommendations on the drug label when prescribing bisphosphonates and advise patients of the potential risks. Patients with pain in the hips, thighs or femur should be radiologically assessed and, where a stress fracture is evident, the physician should decide whether bisphosphonate therapy should be discontinued pending a full evaluation, based on an individual benefit–risk assessment. The radiographic changes should be evaluated for orthopaedic intervention—since surgery prior to fracture completion might be advantageous—or be closely monitored.

Acknowledgements

The Working Group meeting was supported by an unrestricted educational grant from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis. Editorial assistance for the manuscript was provided by Sola Neunie of BioScience Communications, supported by a financial grant from Novartis Pharmaceuticals.

Conflicts of interest

Rene Rizzoli has attended paid advisory boards and received consultancy and lecturing fees from Servier, Novartis, Eli Lilly, Amgen, Roche, Nycomed, Merck Sharp and Dohme and Danone. Kristina Åkesson has received lecturing fees from Medtronics, Novartis, Amgen, Merck and Nycomed. Mary Bouxsein has undertaken consultancy and lecturing commitments for Amgen and Merck & Co. John A. Kanis consults or has received research support from a large number of pharmaceutical companies involved in marketing products for treatment of osteoporosis. He is president of the International Osteoporosis Foundation and serves on its Committee of Scientific Advisors. Nicola Napoli has received grant support from Merck Sharpe and Dohme. Socrates Papapoulos has received consultancy and lecturing fees from Alliance for Better Bone Health, Amgen, Eli Lilly, GSK, Merck & Co, Novartis, Pfizer and Roche. Jean-Yves Reginster has received consulting fees and attended paid advisory boards for Servier, Novartis, Negma, Lilly, Wyeth, Amgen, GlaxoSmithKline, Roche, Merckle, Nycomed, NPS, Theramex and UCB. He has received invited lecture fees from Merck Sharp and Dohme, Lilly, Rottapharm, IBSA, Genevrier, Novartis, Servier, Roche, GlaxoSmithKline, Teijin, Teva, Ebewee Pharma, Zodiac, Analis, Theramex, Nycomed and Novo Nordisk. He has received grant support from Bristol Myers Squibb, Merck Sharp & Dohme, Rottapharm, Teva, Lilly, Novartis, Roche, GlaxoSmithKline, Amgen and Servier. Cyrus Cooper has undertaken consultancy and lecturing commitments for Alliance for Better Bone Health, Eli Lilly, Novartis, GSK Roche, Servier, MSD and Amgen.

Open Access

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

Copyright information

© The Author(s) 2010

Authors and Affiliations

  • R. Rizzoli
    • 1
  • K. Åkesson
    • 2
  • M. Bouxsein
    • 3
  • J. A. Kanis
    • 4
  • N. Napoli
    • 5
  • S. Papapoulos
    • 6
  • J.-Y. Reginster
    • 7
  • C. Cooper
    • 8
    • 9
  1. 1.Division of Bone Diseases, Department of Rehabilitation and GeriatricsUniversity Hospitals and Faculty of Medicine of GenevaGeneva 14Switzerland
  2. 2.Department of Orthopedics Malmö, Skåne University HospitalLund UniversityLundSweden
  3. 3.Department of Orthopaedic SurgeryHarvard Medical School Center for Advanced Orthopaedic Studies, Beth Israel Deaconess Medical CenterBostonUSA
  4. 4.WHO Collaborating Centre for Metabolic Bone DiseasesUniversity of Sheffield Medical SchoolSheffieldUK
  5. 5.Division of EndocrinologyUniversita’ Campus Bio-Medico di RomaRomeItaly
  6. 6.Department of Endocrinology and Metabolic DiseasesLeiden University Medical CenterLeidenThe Netherlands
  7. 7.Department of Public Health Sciences and Department of Physical Medicine and RehabilitationUniversity of LiègeLiègeBelgium
  8. 8.MRC Epidemiology Resource CentreUniversity of SouthamptonSouthamptonUK
  9. 9.NIHR Musculoskeletal Biomedical Research UnitUniversity of OxfordOxfordUK

Personalised recommendations